-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pro-Dex (NASDAQ:PDEX) Coverage Initiated at StockNews.com
Pro-Dex (NASDAQ:PDEX) Coverage Initiated at StockNews.com
Analysts at StockNews.com initiated coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Rating) in a report issued on Wednesday. The brokerage set a "hold" rating on the medical instruments supplier's stock.
Pro-Dex Trading Up 1.6 %
Shares of NASDAQ:PDEX opened at $17.79 on Wednesday. The company has a quick ratio of 1.39, a current ratio of 2.73 and a debt-to-equity ratio of 0.41. Pro-Dex has a 12-month low of $12.40 and a 12-month high of $26.50. The firm has a fifty day moving average of $18.19 and a two-hundred day moving average of $17.19. The firm has a market capitalization of $63.69 million, a P/E ratio of 17.11 and a beta of 0.91.
Get Pro-Dex alerts:Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in PDEX. Tower Research Capital LLC TRC boosted its position in Pro-Dex by 345.6% in the third quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier's stock valued at $48,000 after buying an additional 2,084 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Pro-Dex during the second quarter worth $168,000. State Street Corp increased its position in shares of Pro-Dex by 5.8% during the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock worth $197,000 after acquiring an additional 650 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Pro-Dex by 59.2% during the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock worth $345,000 after purchasing an additional 7,762 shares during the last quarter. Finally, LSV Asset Management boosted its holdings in Pro-Dex by 13.9% during the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock worth $588,000 after purchasing an additional 4,346 shares during the last quarter. Institutional investors own 13.69% of the company's stock.
About Pro-Dex
(Get Rating)Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
See Also
- Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
Analysts at StockNews.com initiated coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Rating) in a report issued on Wednesday. The brokerage set a "hold" rating on the medical instruments supplier's stock.
斯托克新闻网的分析师在周三发布的一份报告中开始对Pro-Dex(纳斯达克代码:PDEX-GET Rating)的股票进行报道。该经纪公司对这家医疗器械供应商的股票设定了“持有”评级。
Pro-Dex Trading Up 1.6 %
Pro-Dex交易上涨1.6%
Shares of NASDAQ:PDEX opened at $17.79 on Wednesday. The company has a quick ratio of 1.39, a current ratio of 2.73 and a debt-to-equity ratio of 0.41. Pro-Dex has a 12-month low of $12.40 and a 12-month high of $26.50. The firm has a fifty day moving average of $18.19 and a two-hundred day moving average of $17.19. The firm has a market capitalization of $63.69 million, a P/E ratio of 17.11 and a beta of 0.91.
纳斯达克:PDEX的股票周三开盘报17.79美元。该公司的速动比率为1.39,流动比率为2.73,债务权益比率为0.41。Pro-Dex的12个月低点为12.40美元,12个月高位为26.50美元。该公司的50日移动均线切入位为18.19美元,200日移动均线切入位为17.19美元。该公司的市值为6369万美元,市盈率为17.11倍,贝塔系数为0.91。
Institutional Inflows and Outflows
机构资金流入和流出
Several institutional investors and hedge funds have recently made changes to their positions in PDEX. Tower Research Capital LLC TRC boosted its position in Pro-Dex by 345.6% in the third quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier's stock valued at $48,000 after buying an additional 2,084 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Pro-Dex during the second quarter worth $168,000. State Street Corp increased its position in shares of Pro-Dex by 5.8% during the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock worth $197,000 after acquiring an additional 650 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Pro-Dex by 59.2% during the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock worth $345,000 after purchasing an additional 7,762 shares during the last quarter. Finally, LSV Asset Management boosted its holdings in Pro-Dex by 13.9% during the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock worth $588,000 after purchasing an additional 4,346 shares during the last quarter. Institutional investors own 13.69% of the company's stock.
几家机构投资者和对冲基金最近改变了他们在PDEX的头寸。Tower Research Capital LLC TRC在第三季度将其在Pro-Dex的头寸增加了345.6%。Tower Research Capital LLC TRC在上个季度额外购买了2,084股后,现在拥有这家医疗器械供应商2,687股股票,价值48,000美元。复兴科技有限责任公司在第二季度购买了Pro-Dex价值16.8万美元的新股。道富集团在第一季度将Pro-Dex股票的头寸增加了5.8%。道富集团目前持有这家医疗器械供应商11,923股股票,价值19.7万美元,此前该公司在上个季度又收购了650股。摩根大通在第一季度增持了59.2%的Pro-Dex股票。摩根大通公司目前持有这家医疗器械供应商20,863股股票,价值345,000美元。摩根大通在上个季度又购买了7,762股股票。最后,LSV资产管理公司在第一季度将Pro-Dex的持有量增加了13.9%。LSV资产管理公司现在拥有这家医疗器械供应商的35,581股股票,价值58.8万美元,上个季度又购买了4,346股。机构投资者持有该公司13.69%的股份。
About Pro-Dex
关于Pro-Dex
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Pro-Dex公司为世界各地的医疗器械原始设备制造商设计、开发、制造和销售动力手术器械。该公司提供可高压灭菌、电池供电和电动的多功能外科驱动程序和剃须刀,主要用于整形外科、胸部和颅颌面部市场。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- 免费获取StockNews.com Pro-Dex上的研究报告(PDEX)
- 辉瑞、强生能否继续跑赢该指数?
- 这就是为什么达科电子在一天内下跌了40%
- 是时候在Gamestop上认输了吗?
- 为什么你应该避免Carvana,即使它可以避免破产
- 投资者是否听到了Spotify下跌趋势的终结?
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pro-Dex Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pro-Dex和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧